

Supplementary Table 1. Four-cell table of proportional disequilibrium method.

Drugs	Target reaction	adverse	Other reactions	adverse	Total
Target drug	a		b		a+b
Other drugs	c		d		c+d
Total	a+c		b+d		n=a+b+c+d

a: the number of reports containing both the suspect drug and the suspect adverse drug reaction; b: the number of reports containing the suspect adverse drug reaction with other medications (except the drug of interest); c: the number of reports containing the suspect drug with other adverse drug reactions (except the event of interest); d: the number of reports containing other medications and other adverse drug reactions; n: the number of all reports.

Supplementary Table 2. Four major algorithms used for signal detection.

Algorithms	Equation	Criteria
ROR	$ROR = ad/b/c$	Lower limit of 95% $CI > 1, a \geq 3$
	$95\%CI = e^{\ln(ROR) \pm 1.96(1/a + 1/b + 1/c + 1/d)^{0.5}}$	
PRR	$PRR = a(c+d)/c/(a+b)$	$PRR \geq 2, \chi^2 \geq 4, N \geq 3$
	$\chi^2 = [(ad-bc)^2]/(a+b+c+d)/[(a+b)(c+d)(a+c)(b+d)]$	
BCPNN	$IC = \log_2 a(a+b+c+d)/[(a+c)(a+b)]$	$IC_{025} > 0$
	$95\%CI = E(IC) \pm 2V(IC)^{0.5}$	
MGPS	$EBGM = a(a+b+c+d)/[(a+c)(a+b)]$	$EBGM_{05} > 2$
	$95\%CI = e^{\ln(EBGM) \pm 1.96(1/a + 1/b + 1/c + 1/d)^{0.5}}$	

Equation: a, number of reports containing both the target drug and target adverse drug reaction; b, number of reports containing other adverse drug reaction of the target drug; c, number of reports containing the target adverse drug reaction of other drugs; d, number of reports containing other drugs and other adverse drug reactions. 95%CI, 95% confidence interval; N, the number of reports; χ^2 , chi-squared; IC, information component; IC_{025} , the lower limit of 95% CI of the IC; E(IC), the IC expectations; V(IC), the variance of IC; BCPNN, Bayesian Confidence Propagation Neural Network; EBGM, empirical Bayesian geometric mean; $EBGM_{05}$, the lower limit of 95% CI of EBGM; PRR, Proportional Reporting Ratio.

Supplementary Table 3. The top twenty AEs with the highest frequency for cetuximab and panitumumab.

Drug	PTs	Frequency	SOC	ROR (95% CI)
Cetuximab	rash	1619	skin and subcutaneous tissue disorders	4.76 (4.53 - 5)
	off label use	1065	injury, poisoning and procedural complications	1.6 (1.5 - 1.7)
	dyspnoea	957	respiratory, thoracic and mediastinal disorders	2.05 (1.92 - 2.19)
	infusion related reaction	943	injury, poisoning and procedural complications	18.25 (17.1 - 19.47)
	diarrhoea	895	gastrointestinal disorders	1.7 (1.59 - 1.82)
	nausea	843	gastrointestinal disorders	1.29 (1.21 - 1.39)
	vomiting	716	gastrointestinal disorders	1.87 (1.74 - 2.02)
	hypotension	660	vascular disorders	4 (3.71 - 4.32)
	dehydration	656	metabolism and nutrition disorders	5.92 (5.48 - 6.4)
	pyrexia	631	general disorders and administration site conditions	2.16 (2 - 2.34)
	dermatitis	574	skin and subcutaneous tissue disorders	132.56 (121.49 - 144.62)
	acneiform		blood and lymphatic system disorders	5.04 (4.64 - 5.48)
	neutropenia	559	general disorders and administration site conditions	24.66 (22.58 - 26.93)
	mucosal inflammation	511	skin and subcutaneous tissue disorders	1.76 (1.61 - 1.92)
	pruritus	509	blood and lymphatic system disorders	3.04 (2.78 - 3.33)
	anaemia	489	metabolism and nutrition disorders	2.44 (2.23 - 2.68)
	decreased appetite	461	gastrointestinal disorders	5.79 (5.27 - 6.36)
	dysphagia	446	immune system disorders	2.87 (2.61 - 3.15)
	hypersensitivity	439	white blood cell count decreased	4.76 (4.33 - 5.23)
	weight decreased	433	investigations	1.84 (1.67 - 2.02)
Panitumumab	rash	1204	skin and subcutaneous tissue disorders	5.97 (5.63 - 6.32)
	diarrhoea	893	gastrointestinal disorders	2.88 (2.69 - 3.08)
	death	671	general disorders and administration site conditions	1.63 (1.51 - 1.76)
	dermatitis	651	skin and subcutaneous tissue disorders	258.74 (238.16 - 281.1)
	acneiform		metabolism and nutrition	83.35 (76.3 - 91.04)
	hypomagnesaemi	524		

a		disorders	
		blood and lymphatic system	
neutropenia	486	disorders	7.38 (6.74 - 8.07)
nausea	440	gastrointestinal disorders	1.13 (1.03 - 1.24)
		skin and subcutaneous tissue	198.52 (179.73 -
skin toxicity	437	disorders	219.27)
vomiting	386	gastrointestinal disorders	1.69 (1.53 - 1.87)
stomatitis	382	gastrointestinal disorders	12.92 (11.68 - 14.3)
			197.47 (177.17 -
paronychia	366	infections and infestations	220.1)
		skin and subcutaneous tissue	
dry skin	353	disorders	5.79 (5.21 - 6.43)
decreased		metabolism and nutrition	
appetite	344	disorders	3.06 (2.75 - 3.4)
neuropathy			
peripheral	316	nervous system disorders	7.1 (6.35 - 7.93)
		general disorders and	
pyrexia	277	administration site conditions	1.58 (1.41 - 1.78)
		blood and lymphatic system	
anaemia	267	disorders	2.78 (2.46 - 3.14)
		blood and lymphatic system	
thrombocytopenia	260	disorders	4.76 (4.21 - 5.38)
		skin and subcutaneous tissue	
pruritus	249	disorders	1.44 (1.27 - 1.63)
interstitial lung		respiratory, thoracic and	
disease	239	mediastinal disorders	10.33 (9.09 - 11.74)
		general disorders and	
asthenia	237	administration site conditions	1.26 (1.11 - 1.43)

Abbreviations: AEs, adverse events; PTs, preferred terms; ROR, reported odds ratio; SOC, systemic organ classes.

Supplementary Table 4. The top twenty AEs with the strongest signal intensity for cetuximab and panitumumab.

Drug	PT	Frequency	SOC	ROR (95% CI)
Cetuximab	dermatitis acneiform	574	skin and subcutaneous tissue disorders	132.56 (121.49 - 144.62)
	trichomegaly	9	eye disorders	131.59 (65.84 - 263.01)
	pneumonia serratia	3	infections and infestations	91.48 (28.13 - 297.44)
	laryngeal necrosis	3	respiratory, thoracic and mediastinal disorders	84.25 (26.01 - 272.96)
	pharyngeal inflammation	77	respiratory, thoracic and mediastinal disorders	83.46 (66.18 - 105.27)
	mucosal infection	13	infections and infestations	67.69 (38.64 - 118.58)
	nail bed inflammation	16	skin and subcutaneous tissue disorders	65.95 (39.8 - 109.27)
	femoral artery embolism	3	vascular disorders	57.17 (17.9 - 182.66)
	rash follicular	7	skin and subcutaneous tissue disorders	56.6 (26.46 - 121.06)
	granulocyte count decreased	57	investigations	52.54 (40.27 - 68.56)
	paronychia	149	infections and infestations	44.66 (37.9 - 52.62)
	portal venous gas	11	gastrointestinal disorders	38.75 (21.23 - 70.72)
	skin toxicity	139	skin and subcutaneous tissue disorders	34.66 (29.27 - 41.05)
	pharyngeal stenosis	3	respiratory, thoracic and mediastinal disorders	34.43 (10.9 - 108.7)
	hypomagnesaemia	369	metabolism and nutrition disorders	34.22 (30.84 - 37.97)
	tracheostomy infection	3	infections and infestations	31.7 (10.05 - 99.95)
	nail bed tenderness	3	skin and subcutaneous tissue disorders	31.08 (9.86 - 97.97)
	cutaneous symptom	15	skin and subcutaneous tissue disorders	29.38 (17.59 - 49.08)
	thrombophlebitis			
	migrans	6	vascular disorders	26.91 (11.97 - 60.5)
Panitumumab	mucosal inflammation	511	general disorders and administration site conditions	24.66 (22.58 - 26.93)
	trichomegaly	22	eye disorders	26.93 (17.59 - 402.4 -

			1069.28)
dermatitis acneiform	651	skin and subcutaneous tissue disorders	258.74 (238.16 - 281.1)
skin toxicity	437	skin and subcutaneous tissue disorders	198.52 (179.73 - 219.27)
paronychia	366	infections and infestations	197.47 (177.17 - 220.1)
xeroderma	14	skin and subcutaneous tissue disorders	121.55 (70.73 - 208.88)
adjusted calcium decreased	6	investigations	115.36 (50.52 - 263.4)
eyelash changes	7	eye disorders	94.82 (44.33 - 202.81)
nail bed inflammation	13	skin and subcutaneous tissue disorders	88.74 (50.84 - 154.9)
xerosis	48	general disorders and administration site conditions	87.43 (65.42 - 116.84)
hypomagnesaemia	524	metabolism and nutrition disorders	83.35 (76.3 - 91.04)
ectropion	13	eye disorders	81.29 (46.62 - 141.74)
mucocutaneous rash	5	skin and subcutaneous tissue disorders	77.07 (31.48 - 188.67)
dermatophytosis of nail	4	infections and infestations	74.5 (27.4 - 202.56)
acne pustular	26	infections and infestations	65.34 (44.17 - 96.65)
stoma site ulcer	5	injury, poisoning and procedural complications	64.78 (26.54 - 158.12)
growth of eyelashes	24	eye disorders	59.22 (39.43 - 88.96)
dermatitis infected	13	infections and infestations	53.57 (30.85 - 93.02)
eyelash thickening	3	eye disorders	50.13 (15.91 - 157.9)
rash pustular	165	infections and infestations	44.39 (38.02 - 51.82)
urinoma	3	renal and urinary disorders	41.26 (13.13 - 129.61)

Abbreviations: AEs, adverse events; PTs, preferred terms; ROR, reported odds ratio; SOC, systemic organ classes.

Supplementary Table 5. Signal strength of reports of cetuximab and panitumumab at the PT level in the FAERS database.

SOC system	Cetuximab			Panitumumab		
	PTs	N	ROR (95% CI)	PTs	N	ROR (95% CI)
BLOOD AND LYMPHATIC SYSTEM DISORDERS			5.04 (4.64 -			7.38 (6.74 -
	neutropenia	559	5.48)	neutropenia	486	8.07)
			3.04 (2.78 -			2.78 (2.46 -
	anaemia	489	3.33)	anaemia	267	3.14)
			3.92 (3.53 -			4.76 (4.21 -
	thrombocytopenia	359	4.35)	thrombocytopenia	260	5.38)
			6.22 (5.58 -			7.26 (6.37 -
	febrile neutropenia	330	6.93)	febrile neutropenia	230	8.26)
			6.73 (5.98 -			4.66 (3.88 -
	leukopenia	277	7.58)	leukopenia	115	5.59)
			15.23 (13.45 -			3.82 (2.81 -
	myelosuppression	252	17.26)	bone marrow failure	41	5.19)
			7.73 (6.53 -			1.4 (1.02 -
	bone marrow failure	138	9.14)	pancytopenia	38	1.93)
			1.79 (1.44 -			2.69 (1.84 -
	pancytopenia	81	2.22)	myelosuppression	27	3.92)
						5.82 (3.89 -
	lymphopenia	58	5 (3.87 - 6.48)	haematotoxicity	24	8.68)
	disseminated			disseminated		
	intravascular		4.39 (3.35 -	intravascular		
	coagulation	53	5.75)	coagulation	22	3.04 (2 - 4.62)
			3.33 (2.21 -			10.62 (6.91 -
	haematotoxicity	23	5.01)	febrile bone marrow		16.31)
	febrile bone marrow		6.64 (4.37 -	aplasia	21	2.3 (1.41 -
	aplasia	22	10.1)			3.76)
CARDIAC DISORDERS			3.76 (2.4 -	lymphopenia	16	2.65 (1.32 -
	granulocytopenia	19	5.91)	granulocytopenia	8	5.3)
	white blood cell		3.05 (1.45 -	lymphadenopathy		5.35 (2.22 -
	disorder	7	6.41)	mediastinal	5	12.86)
				thrombotic		
			2.83 (1.17 -	thrombocytopenic		2.78 (1.16 -
	microcytic anaemia	5	6.8)	purpura	5	6.7)
	/	/	/	thrombocytopenic		4.22 (1.36 -
			2.56 (2.21 -	purpura	3	13.11)
	tachycardia	188	2.95)	cardiopulmonary		2.98 (1.34 -
	cardio-respiratory		4.69 (4.03 -	failure	6	6.63)
	arrest	167	5.46)	/	/	/
	cardiac arrest	139	2 (1.69 - 2.37)	/	/	/

	atrial fibrillation	124	1.52 (1.27 - 1.81)	/	/	/
	acute myocardial infarction	52	2.03 (1.55 - 2.67)	/	/	/
	sinus tachycardia	38	3.2 (2.32 - 4.39)	/	/	/
	angina pectoris	37	1.48 (1.07 - 2.04)	/	/	/
	myocardial ischaemia	32	3.13 (2.21 - 4.43)	/	/	/
	ventricular tachycardia	28	2.02 (1.4 - 2.93)	/	/	/
	supraventricular tachycardia	18	2.22 (1.4 - 3.53)	/	/	/
	acute coronary syndrome	16	2.21 (1.35 - 3.61)	/	/	/
	atrial flutter	15	2.19 (1.32 - 3.63)	/	/	/
	stress cardiomyopathy	13	2.94 (1.71 - 5.07)	/	/	/
	arrhythmia supraventricular	6	6.24 (2.79 - 13.91)	/	/	/
	diastolic dysfunction	6	2.32 (1.04 - 5.18)	/	/	/
	prinzmetal angina	5	6 (2.49 - 14.46)	/	/	/
	cardiovascular insufficiency	4	2.77 (1.04 - 7.4)	/	/	/
	left atrial dilatation	4	3.61 (1.35 - 9.64)	/	/	/
	mitral valve calcification	3	5.65 (1.82 - 17.56)	/	/	/
	nodal arrhythmia	3	3.98 (1.28 - 12.36)	/	/	/
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	k-ras gene mutation	3	52.49 (16.47 - 167.28)	gene mutation	34	35.5 (25.28 - 49.86)
	/	/	/	k-ras gene mutation	6	184.97 (79.8 - 428.72)
	/	/	/	braf gene mutation	5	120.81 (48.84 - 298.85)
	/	/	/	acquired gene mutation	4	6.38 (2.39 - 17.03)
	/	/	/			

ENDOCRINE DISORDERS	/	/	/	phimosis	3	8.61 (2.77 - 26.77)
	hypercalcaemia of malignancy	3	14.82 (4.74 - 46.32)	/	/	/
	blepharitis	25	8.18 (5.52 - 12.12)	eye irritation	38	1.56 (1.13 - 2.14)
	ulcerative keratitis	17	7.67 (4.76 - 12.37)	ocular hyperaemia	34	1.58 (1.13 - 2.21)
	periorbital oedema	11	2.59 (1.43 - 4.67)	growth of eyelashes	24	59.22 (39.43 - 88.96)
	growth of eyelashes	10	14.44 (7.74 - 26.96)	trichomegaly	22	655.96 (402.4 - 1069.28)
	ocular toxicity	9	13.25 (6.87 - 25.57)	blepharitis	21	11.5 (7.49 - 17.66)
	trichomegaly	9	131.59 (65.84 - 263.01)	keratitis	18	12.54 (7.89 - 19.93)
	keratitis	9	3.73 (1.94 - 7.17)	ocular toxicity	13	32.25 (18.63 - 55.81)
	serous retinal detachment	8	14.72 (7.33 - 29.58)	eye discharge	13	2.78 (1.61 - 4.79)
EYE DISORDERS	eyelid margin crusting	5	2.51 (1.04 - 6.03)	ectropion	13	81.29 (46.62 - 141.74)
	eyelid disorder	5	2.61 (1.08 - 6.27)	eye inflammation	9	2.04 (1.06 - 3.91)
	corneal perforation	4	7.93 (2.97 - 21.22)	ulcerative keratitis	8	6.03 (3.01 - 12.06)
	corneal erosion	3	6.74 (2.17 - 20.97)	eyelid disorder	7	6.12 (2.91 - 12.85)
	trichiasis	3	11.48 (3.68 - 35.8)	eyelash changes	7	94.82 (44.33 - 202.81)
	/	/	/	xerophthalmia	5	18.98 (7.86 - 45.82)
	/	/	/	conjunctival hyperaemia	5	2.88 (1.2 - 6.93)
	/	/	/	punctate keratitis	3	7.2 (2.32 - 22.37)
	/	/	/	corneal perforation	3	9.95 (3.2 - 30.95)
	/	/	/	conjunctival disorder	3	15.59 (5 - 48.59)
	/	/	/	eyelash thickening	3	50.13 (15.91 - 157.9)
	/	/	/	eye allergy	3	3.97 (1.28 - 12.33)

GASTROINTESTI NAL DISORDERS

		1.7 (1.59 -			2.88 (2.69 -
diarrhoea	895	1.82)	diarrhoea	893	3.08)
		1.29 (1.21 -			1.13 (1.03 -
nausea	843	1.39)	nausea	440	1.24)
		1.87 (1.74 -			1.69 (1.53 -
vomiting	716	2.02)	vomiting	386	1.87)
		5.79 (5.27 -			12.92 (11.68 -
dysphagia	446	6.36)	stomatitis	382	14.3)
					1.44 (1.24 -
stomatitis	398	8 (7.25 - 8.83)	abdominal pain	167	1.68)
		1.4 (1.24 -			3.65 (2.86 -
abdominal pain	272	1.58)	intestinal obstruction	65	4.65)
		3.49 (2.88 -			9.75 (7.51 -
intestinal obstruction	104	4.23)	ileus	57	12.65)
		1.55 (1.28 -			3.73 (2.86 -
dry mouth	103	1.88)	ascites	55	4.86)
		8.6 (6.93 -			1.92 (1.37 -
ileus	84	10.66)	colitis	34	2.69)
		4.33 (3.49 -			1.55 (1.1 -
oral pain	83	5.37)	rectal haemorrhage	34	2.17)
		9.12 (7.33 -			2.41 (1.63 -
oesophagitis	81	11.36)	mouth ulceration	25	3.57)
		2.59 (2.02 -	small intestinal		3.98 (2.67 -
ascites	64	3.31)	obstruction	24	5.94)
		1.89 (1.45 -			4.36 (2.92 -
colitis	56	2.46)	intestinal perforation	24	6.51)
gastrointestinal		13.65 (10.21 -	gastrointestinal		9.87 (6.36 -
toxicity	46	18.26)	toxicity	20	15.32)
		1.95 (1.44 -			5.15 (3.32 -
haematemesis	42	2.65)	aphthous ulcer	20	7.99)
pneumatoxis		18.89 (13.92 -			16.66 (10.48 -
intestinalis	42	25.63)	subileus	18	26.51)
		1.61 (1.19 -			6.86 (4.32 -
swollen tongue	42	2.17)	enterocolitis	18	10.9)
		8.27 (6.03 -			5.89 (3.6 -
odynophagia	39	11.33)	cheilitis	16	9.62)
small intestinal		3.77 (2.74 -			
obstruction	38	5.18)	oesophagitis	16	3 (1.83 - 4.89)
		3.47 (2.45 -	large intestine		4.65 (2.85 -
intestinal perforation	32	4.91)	perforation	16	7.6)
		1.66 (1.16 -	gastrointestinal		7.32 (4.41 -
melaena	31	2.35)	perforation	15	12.15)
		1.73 (1.21 -			4.27 (2.57 -
mouth ulceration	30	2.47)	duodenal ulcer	15	7.09)

enteritis	30	5.95 (4.16 - 8.52)	oral disorder	15	4.09 (2.46 - 6.78)
large intestine perforation	27	4.69 (3.22 - 6.85)	glossitis	15	8.36 (5.03 - 13.88)
cheilitis	24	5.28 (3.54 - 7.89)	proctalgia	13	3.94 (2.28 - 6.78)
gastrointestinal perforation	22	6.42 (4.22 - 9.76)	enteritis	12	3.97 (2.26 - 7)
gastrointestinal necrosis	21	8.68 (5.65 - 13.34)	pneumatosis intestinalis	10	7.43 (3.99 - 13.83)
mouth haemorrhage	20	3.31 (2.14 - 5.14)	lip dry	8	2.12 (1.06 - 4.23)
duodenal ulcer	19	7.74 (4.93 - 12.15)	intestinal ischaemia	7	2.61 (1.24 - 5.48)
haemorrhage	18	4.02 (2.53 - 6.38)	anal haemorrhage	7	5.03 (2.39 - 10.56)
intestinal ischaemia	18	4.47 (2.74 - 7.31)	anorectal discomfort	7	2.57 (1.22 - 5.4)
chapped lips	16	2.72 (1.66 - 4.44)	malignant ascites	6	15.8 (7.07 - 35.3)
duodenal ulcer	16	8.27 (4.98 - 13.75)	large intestinal obstruction	6	5.71 (2.56 - 12.73)
subileus	15	3.18 (1.88 - 5.38)	angular cheilitis	6	19.09 (8.54 - 42.68)
enterocolitis	14	2.2 (1.31 - 3.73)	rectal perforation	6	22.17 (9.91 - 49.59)
tongue disorder	14	2.53 (1.5 - 4.28)	tongue discolouration	6	2.6 (1.17 - 5.8)
proctalgia	14	2.38 (1.38 - 4.1)	tongue discomfort	5	2.49 (1.04 - 5.99)
colitis ischaemic	13	1.9 (1.08 - 3.34)	oesophageal ulcer	5	2.58 (1.07 - 6.21)
lip dry	12	1.84 (1.05 - 3.25)	large intestinal stenosis	5	5.52 (2.29 - 13.28)
aphthous ulcer	12	3.04 (1.68 - 5.49)	colonic fistula	4	13.89 (5.19 - 37.14)
ileus paralytic	11	38.75 (21.23 - 70.72)	oesophageal varices	4	3.68 (1.38 - 9.82)
portal venous gas	11	3.26 (1.8 - 5.89)	haemorrhage	4	15.35 (5.74 - 41.07)
oesophageal pain	11	2.07 (1.11 - 3.86)	mechanical ileus	4	3.93 (1.47 - 10.48)
anal fissure	10	4.5 (2.25 - 9.01)	anorectal disorder	4	2.88 (1.08 - 7.67)
diverticular perforation	8		dyschezia	4	

small intestinal perforation	8	5.25 (2.62 - 10.52)	enterocutaneous fistula	4	8.89 (3.33 - 23.76)
tongue discolouration	8	2.07 (1.04 - 4.15)	proctitis	4	2.84 (1.06 - 7.56)
oesophageal stenosis	8	3.42 (1.71 - 6.85)	anal ulcer	3	7.82 (2.52 - 24.3)
oral mucosal erythema	8	6.21 (3.1 - 12.44)	small intestinal perforation	3	3.29 (1.06 - 10.21)
duodenal perforation	7	9.12 (4.33 - 19.2)	enterocolitis haemorrhagic	3	3.88 (1.25 - 12.05)
glossitis	7	2.32 (1.11 - 4.87)	oral mucosal eruption	3	3.99 (1.28 - 12.38)
tongue haemorrhage	7	7.6 (3.61 - 15.99)	tongue dry	3	4.4 (1.42 - 13.65)
oesophageal ulcer	7	2.16 (1.03 - 4.54)	small intestine ulcer	3	9.51 (3.06 - 29.58)
tongue ulceration	7	2.42 (1.15 - 5.09)	ileal perforation	3	9.04 (2.91 - 28.13)
lip haemorrhage	6	5.62 (2.52 - 12.53)	enterovesical fistula	3	8.01 (2.58 - 24.89)
lip pain	6	2.49 (1.12 - 5.55)	anal inflammation	3	8.79 (2.83 - 27.34)
rectal perforation	6	13.23 (5.91 - 29.6)	duodenal perforation	3	6.52 (2.1 - 20.25)
enterocutaneous fistula	6	7.98 (3.58 - 17.83)	/	/	/
oesophageal obstruction	6	8.64 (3.87 - 19.3)	/	/	/
large intestinal ulcer	6	2.67 (1.2 - 5.96)	/	/	/
acute abdomen	5	3.97 (1.65 - 9.56)	/	/	/
oesophageal haemorrhage	5	4.43 (1.84 - 10.67)	/	/	/
necrotising oesophagitis	5	15.93 (6.59 - 38.52)	/	/	/
gastrointestinal ulcer	5	2.63 (1.09 - 6.32)	/	/	/
pneumoperitoneum	5	3.34 (1.39 - 8.02)	/	/	/
intestinal dilatation	5	4.66 (1.94 - 11.23)	/	/	/
saliva altered	4	5.31 (1.99 - 14.18)	/	/	/

**GENERAL
DISORDERS AND
ADMINISTRATIO
N SITE
CONDITIONS**

anal ulcer	4	6.23 (2.33 - 16.65)	/	/	/
oesophageal perforation	4	5.7 (2.13 - 15.23)	/	/	/
salivary gland disorder	4	9.72 (3.63 - 26.03)	/	/	/
oesophageal fistula	4	15.3 (5.7 - 41.06)	/	/	/
rectal tenesmus	3	3.16 (1.02 - 9.82)	/	/	/
anal inflammation	3	5.25 (1.69 - 16.32)	/	/	/
gastric fistula	3	8.8 (2.82 - 27.4)	/	/	/
ileal perforation	3	5.4 (1.74 - 16.79)	/	/	/
colonic fistula	3	6.2 (1.99 - 19.3)	/	/	/
oral cavity fistula	3	6.81 (2.19 - 21.2)	/	/	/
pyrexia	631	2.16 (2 - 2.34)	death	671	1.63 (1.51 - 1.76)
mucosal inflammation	511	24.66 (22.58 - 26.93)	disease progression	449	8.01 (7.29 - 8.79)
asthenia	414	1.31 (1.19 - 1.45)	pyrexia	277	1.58 (1.41 - 1.78)
chills	359	3.63 (3.27 - 4.03)	asthenia	237	1.26 (1.11 - 1.43)
general physical health deterioration	214	2.38 (2.08 - 2.72)	therapy partial responder	169	32.83 (28.18 - 38.24)
chest pain	209	1.33 (1.16 - 1.52)	mucosal inflammation	154	12.19 (10.4 - 14.29)
chest discomfort	162	1.94 (1.67 - 2.27)	general physical health deterioration	131	2.44 (2.05 - 2.9)
adverse event	129	1.7 (1.43 - 2.02)	adverse event	67	1.48 (1.16 - 1.88)
disease progression	120	1.26 (1.05 - 1.5)	xerosis	48	87.43 (65.42 - 116.84)
feeling hot	68	1.31 (1.03 - 1.66)	inflammation	39	1.57 (1.14 - 2.15)
extravasation	63	18.53 (14.44 - 23.77)	therapy	35	1.77 (1.27 - 2.46)
feeling cold	38	1.61 (1.17 - 2.21)	non-responder	24	1.96 (1.31 - 2.92)
			drug resistance		

		2.24 (1.58 -			1.87 (1.15 -
face oedema	32	3.16)	face oedema	16	3.05)
performance status		7 (4.82 -	performance status		5.84 (3.46 -
decreased	28	10.15)	decreased	14	9.87)
		2.68 (1.81 -			1.87 (1.04 -
sudden death	25	3.98)	secretion discharge	11	3.38)
		3.32 (2.16 -			2.03 (1.06 -
hyperthermia	21	5.09)	facial pain	9	3.9)
infusion site		3.56 (2.29 -	infusion site		2.38 (1.19 -
extravasation	20	5.52)	extravasation	8	4.76)
		4.03 (2.57 -			2.48 (1.18 -
necrosis	19	6.32)	necrosis	7	5.21)
temperature		1.8 (1.08 -			39.38 (16.23 -
intolerance	15	2.98)	mucosal toxicity	5	95.54)
		3.3 (1.91 -			8.97 (3.36 -
localised oedema	13	5.69)	mucosal disorder	4	23.97)
		4.32 (2.5 -	administration site		6.76 (2.17 -
hyperpyrexia	13	7.44)	extravasation	3	20.99)
		6.35 (3.6 -	device related		6.72 (2.16 -
infusion site reaction	12	11.2)	thrombosis	3	20.89)
		5.95 (3.2 -	/	/	/
foaming at mouth	10	11.08)			
systemic					
inflammatory		2.14 (1.02 -	/	/	/
response syndrome	7	4.48)			
physical		4.23 (2.01 -	/	/	/
deconditioning	7	8.88)			
		3.06 (1.37 -	/	/	/
catheter site pain	6	6.81)			
		13.75 (5.69 -	/	/	/
pneumatoxis	5	33.23)			
		4.16 (1.56 -	/	/	/
xerosis	4	11.1)			
catheter site		4.63 (1.73 -	/	/	/
discharge	4	12.35)			
		5.9 (2.21 -	/	/	/
pelvic mass	4	15.78)			
		3.57 (1.15 -	/	/	/
mucosal ulceration	3	11.1)			
		5.25 (1.69 -	/	/	/
glassy eyes	3	16.32)			
		13.98 (4.48 -	/	/	/
mucosal toxicity	3	43.67)			
HEPATOBIILIARY hepatic function	73	2.44 (1.94 -	hepatic failure	53	3.51 (2.68 -

DISORDERS

abnormal		3.07)		4.59)
		1.66 (1.22 -	hepatic function	2.18 (1.59 -
hepatic failure	42	2.24)	abnormal	39 2.98)
		1.56 (1.12 -		2.61 (1.88 -
jaundice	36	2.16)	jaundice	36 3.62)
		3.72 (2.61 -		2.34 (1.58 -
hyperbilirubinaemia	31	5.29)	hepatotoxicity	25 3.47)
		4.19 (2.7 -		6.67 (4.25 -
cholangitis	20	6.5)	cholangitis	19 10.47)
portal vein		3.79 (2.04 -		8.03 (4.99 -
thrombosis	10	7.06)	hepatic lesion	17 12.94)
		2.34 (1.11 -		2.81 (1.66 -
jaundice cholestatic	7	4.91)	hyperbilirubinaemia	14 4.74)
		5.69 (2.71 -	venoocclusive liver	
biliary dilatation	7	11.97)	disease	12 8.89)
hepatorenal		2.74 (1.03 -	portal vein	
syndrome	4	7.31)	thrombosis	12 13.46)
hepatic vein		10.93 (3.5 -	hypertransaminaem	
thrombosis	3	34.08)	ia	9 6.3)
		5.14 (1.65 -		3.92 (1.87 -
cholangitis acute	3	15.98)	jaundice cholestatic	7 8.23)
/	/	/		3.17 (1.32 -
			bile duct stone	5 7.61)
/	/	/		3.01 (1.25 -
			hepatic fibrosis	5 7.24)
/	/	/		5.08 (1.64 -
			bile duct stenosis	3 15.79)
/	/	/		49.66 (15.77 -
			biloma	3 156.42)
/	/	/		6.5 (2.09 -
			biliary obstruction	3 20.2)
		2.87 (2.61 -	decreased immune	
hypersensitivity	439	3.15)	responsiveness	27 5.66 (3.88 -
anaphylactic		9.56 (8.67 -		8.25)
reaction	407	10.54)	/	/ /
		6.63 (5.6 -	/	/ /
IMMUNE SYSTEM	anaphylactic shock	134 7.86)	/	/ /
DISORDERS		6.03 (4.75 -	/	/ /
	immunodeficiency	68 7.65)	/	/ /
	anaphylactoid		/	/ /
	reaction	23 6.74 (4.47 -		
		10.15)	/	/ /
	cytokine release		/	/ /
	syndrome	22 1.92 (1.26 -		
		2.91)		

INFECTIONS AND INFESTATIONS	infusion related hypersensitivity reaction	8	23.14 (11.49 - 46.62)	/	/	/
	cytokine storm	3	5.68 (1.83 - 17.65)	/	/	/
	pneumonia	400	1.51 (1.37 - 1.66)	paronychia	366	197.47 (177.17 - 220.1)
	sepsis	263	2.83 (2.5 - 3.19)	rash pustular	165	44.39 (38.02 - 51.82)
	paronychia	149	44.66 (37.9 - 52.62)	urinary tract infection	121	1.43 (1.19 - 1.7)
	pneumonia aspiration	137	6.69 (5.65 - 7.91)	sepsis	111	1.99 (1.65 - 2.4)
	septic shock	122	3.52 (2.95 - 4.21)	infection	97	1.38 (1.13 - 1.69)
	rash pustular	97	15.37 (12.57 - 18.78)	conjunctivitis	84	9.66 (7.8 - 11.98)
	staphylococcal infection	86	3.04 (2.46 - 3.76)	folliculitis	78	18.23 (14.58 - 22.79)
	cellulitis	80	1.84 (1.48 - 2.3)	device related infection	55	6.9 (5.29 - 8.99)
	conjunctivitis	69	4.73 (3.73 - 5.99)	septic shock	32	1.54 (1.09 - 2.18)
	device related infection	53	3.97 (3.03 - 5.19)	skin infection	26	4.72 (3.21 - 6.93)
	skin infection	36	3.9 (2.81 - 5.41)	acne pustular	26	65.34 (44.17 - 96.65)
	peritonitis	34	1.94 (1.39 - 2.72)	neutropenic sepsis	24	6.57 (4.4 - 9.81)
	folliculitis	33	4.57 (3.24 - 6.43)	pustule	20	21.07 (13.56 - 32.75)
	meningitis aseptic	33	9.26 (6.57 - 13.05)	abscess	17	2.09 (1.3 - 3.36)
	bacteraemia	31	3.3 (2.32 - 4.69)	gastroenteritis	17	2.33 (1.45 - 3.75)
	pneumonia bacterial	24	3.33 (2.23 - 4.98)	pyelonephritis	15	3.5 (2.11 - 5.8)
	staphylococcal sepsis	22	5.14 (3.38 - 7.81)	subcutaneous abscess	15	6.09 (3.67 - 10.11)
	oral candidiasis	19	1.8 (1.15 - 2.83)	abdominal abscess	15	6.96 (4.19 - 11.55)
	neutropenic sepsis	18	2.94 (1.85 - 4.67)	dermatitis infected	13	53.57 (30.85 - 93.02)
	wound infection	17	2.11 (1.31 -	furuncle	13	3.2 (1.85 -

		3.39)			5.51)
		12.44 (7.48 -			7.14 (4.05 -
nail infection	15	20.7)	necrotising fasciitis	12	12.58)
		67.69 (38.64 -			4.13 (2.29 -
mucosal infection	13	118.58)	anal abscess	11	7.47)
		10.34 (5.99 -	pneumocystis		2.16 (1.16 -
superinfection	13	17.86)	jirovecii pneumonia	10	4.01)
staphylococcal		3.51 (1.99 -			17.64 (9.46 -
bacteraemia	12	6.19)	pelvic abscess	10	32.88)
		1.83 (1.04 -			3.9 (2.1 -
escherichia infection	12	3.23)	staphylococcal sepsis	10	7.26)
		3.95 (2.24 -			3.5 (1.82 -
clostridial infection	12	6.96)	erysipelas	9	6.73)
pneumonia		6.61 (3.66 -	staphylococcal skin		14.39 (7.47 -
staphylococcal	11	11.97)	infection	9	27.74)
		2.76 (1.49 -			9.29 (4.42 -
abdominal abscess	10	5.14)	superinfection	7	19.52)
		13.18 (6.83 -			2.42 (1.15 -
acne pustular	9	25.43)	herpes virus infection	7	5.08)
		2.14 (1.11 -			9.67 (4.6 -
endocarditis	9	4.11)	nail infection	7	20.32)
		4.7 (2.35 -	vascular device		3.21 (1.53 -
lung abscess	8	9.42)	infection	7	6.75)
enterocolitis		9.74 (4.85 -			3.27 (1.47 -
infectious	8	19.53)	catheter site infection	6	7.29)
intervertebral		4.56 (2.17 -	conjunctivitis		32.61 (14.54 -
discitis	7	9.58)	bacterial	6	73.12)
		4.64 (2.21 -	pneumonia		6.03 (2.7 -
soft tissue infection	7	9.75)	staphylococcal	6	13.43)
neutropenic		8.33 (3.96 -			8.32 (3.73 -
infection	7	17.52)	impetigo	6	18.56)
oesophageal		2.21 (1.05 -	superinfection		17 (7.61 -
candidiasis	7	4.65)	bacterial	6	37.99)
catheter site		2.28 (1.09 -			3.81 (1.71 -
infection	7	4.78)	liver abscess	6	8.49)
		4.83 (2.17 -	staphylococcal		2.45 (1.02 -
fungaemia	6	10.78)	bacteraemia	5	5.88)
pneumonia		13.34 (5.96 -			4.06 (1.52 -
necrotising	6	29.85)	infected skin ulcer	4	10.82)
pneumonia		3.98 (1.79 -			3.78 (1.42 -
klebsiella	6	8.88)	device related sepsis	4	10.07)
post procedural		11.73 (5.25 -			4.31 (1.62 -
sepsis	6	26.22)	dysentery	4	11.51)
purulence	5	2.88 (1.2 -	abdominal infection	4	3.19 (1.2 -

		6.92)			8.51)
		4.14 (1.72 -	dermatophytosis of		74.5 (27.4 -
impetigo	5	9.96)	nail	4	202.56)
		11.78 (4.88 -			9.77 (3.66 -
pyoderma	5	28.44)	abdominal sepsis	4	26.1)
wound infection		3.21 (1.33 -			33.89 (12.6 -
staphylococcal	5	7.72)	nail bed infection	4	91.15)
		2.82 (1.17 -			3.85 (1.44 -
device related sepsis	5	6.78)	purulence	4	10.27)
endocarditis		12.13 (5.02 -			5.35 (1.72 -
staphylococcal	5	29.28)	febrile infection	3	16.61)
		3.22 (1.34 -			10.12 (3.25 -
dysentery	5	7.75)	biliary tract infection	3	31.48)
postoperative		9.03 (3.74 -			5.4 (1.74 -
abscess	5	21.77)	klebsiella sepsis	3	16.78)
		4.6 (1.91 -	enterocolitis		6.08 (1.96 -
clostridium colitis	5	11.06)	infectious	3	18.89)
		3.43 (1.43 -			9.04 (2.91 -
enteritis infectious	5	8.26)	postoperative abscess	3	28.13)
staphylococcal skin		3.8 (1.42 -			7.38 (2.37 -
infection	4	10.15)	hepatitis viral	3	22.93)
		6.2 (2.32 -			7.32 (2.35 -
tracheobronchitis	4	16.58)	lymphangitis	3	22.74)
		3.37 (1.26 -	pneumonia		5.54 (1.78 -
pulmonary sepsis	4	9.01)	streptococcal	3	17.19)
		9.64 (3.6 -	/	/	/
dermatitis infected	4	25.79)	/	/	/
		6.19 (2.32 -	/	/	/
extradural abscess	4	16.53)	/	/	/
biliary tract		8.07 (3.02 -	/	/	/
infection	4	21.58)	/	/	/
		6.71 (2.51 -	/	/	/
sputum purulent	4	17.94)	/	/	/
		2.8 (1.05 -	/	/	/
pseudomonal sepsis	4	7.48)	/	/	/
		3.37 (1.26 -	/	/	/
meningitis bacterial	4	8.99)	/	/	/
		5.83 (2.18 -	/	/	/
abdominal sepsis	4	15.58)	/	/	/
		4.72 (1.52 -	/	/	/
tracheitis	3	14.66)	/	/	/
alpha haemolytic					
streptococcal		4.01 (1.29 -	/	/	/
infection	3	12.45)	/	/	/

INJURY, POISONING AND PROCEDURAL COMPLICATIONS	infected fistula	3	6.52 (2.1 - 20.29)	/	/	/
	endocarditis bacterial	3	4.61 (1.48 - 14.32)	/	/	/
	pyuria	3	3.54 (1.14 - 10.99)	/	/	/
	nail bed infection	3	15.1 (4.83 - 47.2)	/	/	/
	skin bacterial infection	3	4.76 (1.53 - 14.81)	/	/	/
	tracheostomy infection	3	31.7 (10.05 - 99.95)	/	/	/
	biliary sepsis	3	7.38 (2.37 - 22.96)	/	/	/
	pneumonia serratia	3	91.48 (28.13 - 297.44)	/	/	/
	febrile infection	3	3.19 (1.03 - 9.91)	/	/	/
	klebsiella sepsis	3	3.22 (1.04 - 10.01)	/	/	/
	off label use	1065	1.6 (1.5 - 1.7)	product storage error	121	3.44 (2.88 - 4.11)
	infusion related reaction	943	18.25 (17.1 - 19.47)	infusion related reaction	108	3.4 (2.81 - 4.1)
				circumstance or information capable of leading to		
	radiation skin injury	176	211.77 (180.11 - 249)	medication error	98	6.43 (5.27 - 7.84)
	radiation mucositis	39	365.37 (253.97 - 525.63)	intercepted product administration error	23	6.7 (4.45 - 10.1)
	post procedural haemorrhage	25	2.51 (1.69 - 3.71)	spinal compression fracture	18	3.89 (2.45 - 6.18)
	radiation pneumonitis	20	11.22 (7.22 - 17.43)	post procedural complication	17	1.72 (1.07 - 2.77)
	skin wound	12	9.62 (5.45 - 16.99)	intercepted product preparation error	15	3.02 (1.82 - 5.01)
	radiation injury	12	13.7 (7.75 - 24.21)	occupational exposure to product	12	3.76 (2.13 - 6.63)
	osteoradionecrosis	11	55.91 (30.49 - 102.52)	skin laceration	12	2.27 (1.29 - 3.99)
	recall phenomenon	9	13.05 (6.76 - 25.19)	stoma site haemorrhage	10	13.09 (7.03 - 24.39)
	stoma site haemorrhage	8	6.24 (3.11 - 12.51)	sunburn	9	2.34 (1.22 - 4.5)

INVESTIGATIONS	tracheostomy malfunction	7	41.05 (19.29 - 87.34)	product preparation issue	9	3.81 (1.98 - 7.33)
	tracheal haemorrhage	5	16.99 (7.02 - 41.12)	skin injury	8	4.9 (2.45 - 9.82)
	jaw fracture	5	2.64 (1.1 - 6.34)	gastrointestinal stoma complication	7	8.77 (4.17 - 18.43)
	radiation dysphagia	5	156.95 (61.38 - 401.32)	stoma complication	7	12.78 (6.08 - 26.89)
	radiation oesophagitis	5	15.42 (6.38 - 37.29)	radiation skin injury	7	11.82 (5.62 - 24.85)
	gastrointestinal stoma complication	5	3.73 (1.55 - 8.99)	mouth injury	6	7.85 (3.52 - 17.5)
	endotracheal intubation complication	4	7.91 (2.96 - 21.14)	anastomotic leak	6	17.56 (7.86 - 39.24)
	arterial injury	4	6.33 (2.37 - 16.93)	stoma site ulcer	5	64.78 (26.54 - 158.12)
	injection related reaction	4	3.36 (1.26 - 8.98)	procedural haemorrhage	5	2.81 (1.17 - 6.76)
	procedural site reaction	4	8.99 (3.36 - 24.05)	post procedural bile leak	5	30 (12.39 - 72.61)
	gastroenteritis	4	14.28 (5.32 - 38.29)	skin wound	5	6.68 (2.78 - 16.08)
	radiation	4	5.1 (1.64 - 15.85)	eschar	5	12.79 (5.31 - 30.83)
	suture rupture	3	18.3 (5.84 - 57.28)	stoma site inflammation	4	10.23 (3.83 - 27.34)
	radiation associated pain	3	19.06 (6.08 - 59.69)	burn oral cavity	4	14.08 (5.26 - 37.66)
	gastrostomy tube site complication	3	25.61 (8.15 - 80.5)	eye injury	4	2.75 (1.03 - 7.33)
	tracheal injury	3	/	stoma site pain	3	3.76 (1.21 - 11.67)
	/	/	/	subcutaneous haematoma	3	4.52 (1.46 - 14.04)
	/	/	/	nail injury	3	10.5 (3.37 - 32.65)
	/	/	/	postoperative adhesion	3	8.21 (2.64 - 25.54)
	/	/	/	gastrointestinal anastomotic leak	3	14.9 (4.78 - 46.42)
	white blood cell count decreased	434	4.76 (4.33 - 5.23)	neutrophil count decreased	194	9.77 (8.48 - 11.26)
	weight decreased	433	1.84 (1.67 -	platelet count	115	2.13 (1.78 -

		2.02)	decreased		2.56)
neutrophil count		8.59 (7.64 -	blood magnesium		26.49 (21.98 -
decreased	285	9.65)	decreased	112	31.94)
platelet count			white blood cell		2.04 (1.69 -
decreased	270	3 (2.66 - 3.38)	count decreased	112	2.46)
blood pressure		4.68 (4.15 -	carcinoembryonic		56.73 (43.15 -
decreased	260	5.29)	antigen increased	53	74.59)
			alanine		
oxygen saturation		5.23 (4.6 -	aminotransferase		1.56 (1.18 -
decreased	234	5.95)	increased	49	2.07)
			aspartate		
haemoglobin		1.91 (1.65 -	aminotransferase		1.81 (1.37 -
decreased	169	2.23)	increased	49	2.39)
aspartate					
aminotransferase		2.89 (2.44 -	blood bilirubin		
increased	131	3.44)	increased	38	2.75 (2 - 3.79)
alanine			blood alkaline		
aminotransferase		2.41 (2.02 -	phosphatase		2.31 (1.61 -
increased	126	2.87)	increased	30	3.3)
blood magnesium		16.8 (14.01 -	blood potassium		1.71 (1.17 -
decreased	119	20.13)	decreased	26	2.52)
blood creatinine		1.59 (1.29 -	tumour marker		8.99 (5.91 -
increased	89	1.96)	increased	22	13.66)
blood bilirubin		3.12 (2.48 -	blood calcium		3.26 (2.08 -
increased	72	3.93)	decreased	19	5.11)
blood alkaline					
phosphatase		3.13 (2.47 -	blood albumin		3.23 (1.87 -
increased	68	3.97)	decreased	13	5.56)
		14.64 (11.32 -			6.72 (3.81 -
pulse absent	59	18.93)	amylase increased	12	11.85)
granulocyte count		52.54 (40.27 -	carbohydrate antigen		37.6 (19.43 -
decreased	57	68.56)	19-9 increased	9	72.77)
blood potassium		1.93 (1.46 -	blood magnesium		22.73 (10.16 -
decreased	49	2.55)	abnormal	6	50.85)
blood sodium		2.75 (2.04 -	adjusted calcium		115.36 (50.52 -
decreased	43	3.71)	decreased	6	263.4)
body temperature		2.38 (1.76 -	blood phosphorus		2.75 (1.15 -
increased	43	3.21)	decreased	5	6.62)
			eastern cooperative		
			oncology group		
lymphocyte count		2.72 (2.01 -	performance status		6.9 (2.58 -
decreased	42	3.68)	worsened	4	18.41)
blood pressure		29.99 (21.73 -	staphylococcus test		3.7 (1.39 -
immeasurable	38	41.41)	positive	4	9.87)

haematocrit		1.81 (1.28 -	aspartate		
decreased	32	2.56)	aminotransferase		5.93 (2.22 -
			abnormal	4	15.81)
			blood alkaline		
		1.96 (1.36 -	phosphatase		9.76 (3.65 -
blood urea increased	29	2.82)	abnormal	4	26.07)
blood calcium		2.66 (1.81 -	blood alkaline		32.51 (10.38 -
decreased	26	3.91)	phosphatase	3	101.83)
carcinoembryonic		15.69 (10.57 -	blood bilirubin		4.93 (1.59 -
antigen increased	25	23.29)	abnormal	3	15.3)
blood lactate					
dehydrogenase		1.63 (1.08 -	escherichia test		4.98 (1.6 -
increased	23	2.45)	positive	3	15.47)
blood albumin		2.82 (1.8 -	/	/	/
decreased	19	4.42)	/	/	/
blood culture		6.65 (4.18 -	/	/	/
positive	18	10.57)	/	/	/
respiratory rate		2.25 (1.4 -	/	/	/
increased	17	3.63)	/	/	/
staphylococcus test		7.22 (4.18 -	/	/	/
positive	13	12.45)	/	/	/
culture urine		10.36 (6 -	/	/	/
positive	13	17.9)	/	/	/
blood pressure		3.1 (1.76 -	/	/	/
systolic decreased	12	5.46)	/	/	/
		4.01 (2.28 -	/	/	/
amylase increased	12	7.07)	/	/	/
		1.91 (1.06 -	/	/	/
troponin increased	11	3.45)	/	/	/
		4.98 (2.67 -	/	/	/
pulse abnormal	10	9.27)	/	/	/
pulse pressure		22.14 (11.84 -	/	/	/
decreased	10	41.42)	/	/	/
		51.13 (25.15 -	/	/	/
haemoglobin	8	103.94)	/	/	/
blood magnesium		15.86 (7.52 -	/	/	/
abnormal	7	33.46)	/	/	/
oxygen saturation		98.31 (45.32 -	/	/	/
immeasurable	7	213.22)	/	/	/
sputum culture		9.27 (4.4 -	/	/	/
positive	7	19.51)	/	/	/
bilirubin conjugated		3.05 (1.37 -	/	/	/
increased	6	6.81)	/	/	/

METABOLISM AND NUTRITION DISORDERS	blood electrolytes decreased	6	5.42 (2.43 - 12.09)	/	/	/
	troponin i increased	6	4.37 (1.96 - 9.75)	/	/	/
	computerised tomogram abnormal	5	2.47 (1.03 - 5.94)	/	/	/
	blood electrolytes abnormal	4	3.83 (1.44 - 10.23)	/	/	/
	blood creatine phosphokinase mb increased	4	3.39 (1.27 - 9.06)	/	/	/
	neutrophil count	4	23.72 (8.8 - 63.88)	/	/	/
	laboratory test interference	3	4.33 (1.39 - 13.46)	/	/	/
	procalcitonin increased	3	3.45 (1.11 - 10.72)	/	/	/
	carbohydrate antigen 19-9 increased	3	7.38 (2.37 - 22.96)	/	/	/
	electrocardiogram change	3	3.69 (1.19 - 11.46)	/	/	/
	culture throat positive	3	62.78 (19.59 - 201.15)	/	/	/
	dehydration	656	5.92 (5.48 - 6.4)	hypomagnesaemia	524	83.35 (76.3 - 91.04)
	decreased appetite	461	2.44 (2.23 - 2.68)	decreased appetite	344	3.06 (2.75 - 3.4)
	hypomagnesaemia	369	34.22 (30.84 - 37.97)	dehydration	231	3.46 (3.04 - 3.94)
	hypokalaemia	198	5.24 (4.56 - 6.03)	hypokalaemia	131	5.81 (4.89 - 6.89)
	hyponatraemia	166	3.54 (3.04 - 4.12)	hypocalcaemia	113	12.28 (10.2 - 14.78)
	hypocalcaemia	128	8.3 (6.97 - 9.88)	hyponatraemia	43	1.53 (1.13 - 2.06)
	hyperkalaemia	82	2.87 (2.31 - 3.57)	hyperkalaemia	33	1.93 (1.37 - 2.72)
	hypophagia	80	3.89 (3.12 - 4.85)	electrolyte imbalance	31	5.62 (3.95 - 8)
	hypoalbuminaemia	59	9.27 (7.17 - 11.97)	hyperglycaemia	30	1.65 (1.15 - 2.36)
	malnutrition	57	6.38 (4.92 - 8.28)	hypoalbuminaemia	29	7.59 (5.27 - 10.94)
	electrolyte	48	5.2 (3.92 -	hypophagia	20	1.62 (1.05 -

imbalance		6.91)			2.52)
		1.51 (1.13 -			2.99 (1.83 -
hyperglycaemia	46	2.01)	malnutrition	16	4.88)
		2.42 (1.75 -			3.6 (2.09 -
feeding disorder	36	3.36)	hypophosphataemia	13	6.2)
		5.47 (3.88 -			3.73 (1.94 -
hypophosphataemia	33	7.7)	hyperammonaemia	9	7.17)
		7.07 (4.97 -	tumour lysis		2.15 (1.12 -
cachexia	31	10.07)	syndrome	9	4.14)
		5.14 (3.35 -			8.71 (4.35 -
hypernatraemia	21	7.89)	tetany	8	17.45)
		2.04 (1.33 -			3.04 (1.52 -
hypercalcaemia	21	3.13)	cachexia	8	6.08)
		4.29 (2.73 -			
failure to thrive	19	6.73)	hypernatraemia	7	2.86 (1.36 - 6)
		3.9 (2.49 -			21.72 (9.71 -
hypovolaemia	19	6.12)	hyperamylasaemia	6	48.58)
		2.52 (1.36 -			2.26 (1.02 -
fluid intake reduced	10	4.7)	failure to thrive	6	5.04)
		5.2 (2.6 -			5.28 (2.19 -
tetany	8	10.42)	calciophylaxis	5	12.7)
		13.73 (6.52 -	magnesium		18.67 (6.97 -
hypermagnesaemia	7	28.95)	deficiency	4	50.01)
		5.28 (2.19 -			4.06 (1.52 -
hypochloraemia	5	12.72)	cell death	4	10.83)
		9.77 (3.65 -			3.32 (1.07 -
hypercreatininaemia	4	26.15)	hypoproteinaemia	3	10.31)
		6.44 (2.07 -			9.79 (3.15 -
hyperamylasaemia	3	20.04)	hypermagnesaemia	3	30.44)
magnesium		8.34 (2.68 -	/	/	/
deficiency	3	25.97)			
		7.53 (2.42 -	/	/	/
electrolyte depletion	3	23.45)			

**MUSCULOSKELE
TAL AND
CONNECTIVE
TISSUE
DISORDERS
NEOPLASMS
BENIGN,
MALIGNANT AND
UNSPECIFIED
(INCL CYSTS AND
POLYPS)**

		2.35 (1.26 -			19.72 (6.32 -
trismus	10	4.36)	sarcopenia	3	61.53)
malignant neoplasm		7.95 (7.35 -	colorectal cancer		535.96 (472.66
progression	636	8.6)	metastatic	318	- 607.73)
		5.21 (3.92 -			29.76 (26 -
metastases to lung	48	6.92)	colon cancer	216	34.06)
		2.67 (1.94 -			23.31 (20.23 -
metastases to liver	38	3.67)	metastases to liver	195	26.86)

metastases to central nervous system	30	3 (2.1 - 4.29)	colorectal cancer	146	5.54 (4.71 - 6.52)
neoplasm recurrence	30	10.7 (7.47 - 15.34)	malignant neoplasm progression	125	2.58 (2.17 - 3.08)
tumour haemorrhage	26	11.3 (7.68 - 16.64)	metastases to lung	87	15.92 (12.89 - 19.67)
oncologic complication	26	32.93 (22.29 - 48.66)	adenocarcinoma of colon	41	45.56 (33.41 - 62.12)
metastases to lymph nodes	20	3.77 (2.43 - 5.85)	neoplasm progression	36	1.93 (1.39 - 2.68)
tumour pain	17	15.21 (9.42 - 24.55)	metastases to central nervous system	28	4.69 (3.24 - 6.8)
metastasis colorectal cancer metastatic	16	2.7 (1.65 - 4.41)	metastases to lymph nodes	27	8.54 (5.85 - 12.46)
metastases to spine	13	10.08 (5.84 - 17.4)	colon cancer metastatic	24	30.76 (20.54 - 46.05)
cancer pain	12	4.45 (2.52 - 7.84)	rectal cancer	23	15.17 (10.06 - 22.87)
lymphangiosis carcinomatosa	12	5.74 (3.25 - 10.12)	metastases to peritoneum	22	19 (12.48 - 28.93)
recurrent cancer	11	12.36 (6.82 - 22.39)	metastases to bone	21	2.7 (1.76 - 4.14)
metastases to peritoneum	9	2.8 (1.45 - 5.38)	metastasis colorectal cancer	21	5.95 (3.87 - 9.13)
colon cancer metastatic	9	4.61 (2.39 - 8.87)	recurrent rectal cancer	20	470.75 (287.62 - 770.5)
non-small cell lung cancer	8	6.05 (3.02 - 12.12)	metastatic hepatic neoplasm	17	104.85 (64.29 - 171.02)
squamous cell carcinoma of head and neck	8	2.09 (1.04 - 4.18)		13	7.85 (4.55 - 13.54)
tumour necrosis	6	33.01 (14.65 - 74.39)	adenocarcinoma	11	9.54 (5.27 - 17.25)
tumour perforation	5	5.64 (2.34 - 13.58)	metastases to ovary	10	66.98 (35.62 - 125.93)
bone neoplasm	4	16.81 (6.26 - 45.13)	colon cancer	10	77.75 (41.28 - 146.46)
metastases to abdominal cavity	4	4.33 (1.62 - 11.57)	recurrent cancer	10	7.2 (3.74 - 13.86)
metastases to skin	4	9.93 (3.71 - 26.57)	rectal adenocarcinoma	7	24.74 (11.73 - 52.16)
tumour rupture	4	4.96 (1.86 - 13.24)	metastases to pelvis	7	23.01 (10.92 - 48.5)
	3	7.01 (2.25 -	hepatic cancer	6	13.7 (6.14 -

NERVOUS SYSTEM DISORDERS			21.8)	metastatic		30.59)
	head and neck		5.36 (1.72 -			4.33 (1.94 -
	cancer	3	16.68)	tumour haemorrhage	6	9.65)
	hepatic cancer		4.07 (1.31 -			25.79 (11.52 -
	metastatic	3	12.66)	pyogenic granuloma	6	57.74)
	rectal cancer		10.53 (3.38 -			9.45 (3.92 -
	metastatic	3	32.84)	tumour necrosis	5	22.76)
	metastases to chest		10.85 (3.48 -			35.34 (14.58 -
	wall	3	33.85)	tumour perforation	5	85.64)
	/	/	/			31.37 (11.67 -
	/	/	/	metastases to bladder	4	84.3)
	/	/	/	haemangioma	4	3.72 (1.39 -
	/	/	/	lymphangiosis		9.92)
	/	/	/	carcinomatosa	4	7.47 (2.8 -
	/	/	/	rectosigmoid cancer		19.95)
	/	/	/	metastatic	4	297.99 (103.39
	/	/	/	pancreatic carcinoma		- 858.88)
	/	/	/	metastatic	4	2.72 (1.02 -
	/	/	/			7.25)
	/	/	/			5.93 (2.22 -
	/	/	/	tumour pain	4	15.83)
	/	/	/			12 (4.49 -
	/	/	/	head and neck cancer	4	32.08)
	/	/	/			9.91 (3.19 -
	/	/	/	colon cancer stage iv	3	30.84)
	/	/	/	colorectal		30.47 (9.73 -
	loss of		2.07 (1.82 -	adenocarcinoma	3	95.41)
	consciousness	222	2.37)	neuropathy		7.1 (6.35 -
			1.82 (1.55 -	peripheral	316	7.93)
	syncope	153	2.13)	peripheral sensory		34.83 (28.45 -
	neuropathy		1.95 (1.66 -	neuropathy	96	42.64)
	peripheral	147	2.29)	polyneuropathy	81	14.2 (11.41 -
			2.54 (2.11 -			17.68)
	speech disorder	113	3.06)	neurotoxicity	66	8.28 (6.5 -
	unresponsive to		3.44 (2.73 -			10.55)
	stimuli	72	4.33)	dysgeusia	54	1.4 (1.07 -
			1.44 (1.11 -			1.83)
	coma	57	1.86)	cerebral infarction	23	1.86 (1.23 -
			2.27 (1.7 -	peripheral motor		2.8)
	cerebral infarction	47	3.02)	neuropathy	5	7.22 (3 -
			7.26 (5.16 -			17.38)
	cerebral ischaemia	33	10.23)	acute polyneuropathy	3	25.79 (8.25 -
	neurotoxicity	30	2.24 (1.56 -	cholinergic syndrome	3	80.61)
						9.82 (3.16 -

			3.2)			30.55)
			2.6 (1.75 -			
	polyneuropathy	25	3.85)	/	/	/
	peripheral sensory		3.83 (2.41 -			
	neuropathy	18	6.08)	/	/	/
	peripheral motor		12.16 (7.18 -			
	neuropathy	14	20.59)	/	/	/
			3.34 (1.39 -			
	vocal cord paralysis	5	8.04)	/	/	/
	consciousness		4.8 (1.8 -			
	fluctuating	4	12.81)	/	/	/
			2.77 (1.04 -			
	cerebellar infarction	4	7.4)	/	/	/
	autonomic		3.69 (1.19 -			
	neuropathy	3	11.47)	/	/	/
	mental status		2.51 (1.94 -			
	changes	58	3.25)	/	/	/
			1.54 (1.14 -			
PSYCHIATRIC	delirium	43	2.07)	/	/	/
DISORDERS			1.97 (1.42 -			
	eating disorder	36	2.73)	/	/	/
			2.46 (1.02 -			
	staring	5	5.92)	/	/	/
PRODUCT ISSUES	/	/	/	product temperature		3.17 (1.32 -
				excursion issue	5	7.63)
			1.52 (1.1 -			2.96 (2.03 -
	urinary incontinence	38	2.08)	proteinuria	27	4.31)
			2.9 (1.82 -			5.13 (3.27 -
	hydronephrosis	18	4.6)	hydronephrosis	19	8.04)
			6.93 (3.46 -			2.7 (1.4 -
	ureteric obstruction	8	13.89)	nephrotic syndrome	9	5.19)
	renal tubular		3.29 (1.64 -			3.44 (1.43 -
RENAL AND	disorder	8	6.58)	renal tubular disorder	5	8.27)
URINARY			5.14 (2.3 -			7.49 (3.11 -
DISORDERS	prerenal failure	6	11.46)	iga nephropathy	5	18.02)
	urinary tract		3.01 (1.35 -			5.79 (2.17 -
	obstruction	6	6.71)	ureteric obstruction	4	15.44)
	glomerulonephritis		4.61 (1.73 -			41.26 (13.13 -
	rapidly progressive	4	12.31)	urinoma	3	129.61)
			3.59 (1.16 -			4.29 (1.38 -
	ureterolithiasis	3	11.16)	prerenal failure	3	13.33)
			10.43 (3.34 -			
	hydroureter	3	32.52)	/	/	/

REPRODUCTIVE SYSTEM AND BREAST DISORDERS	genital erythema	3	8.25 (2.65 - 25.7)	genital rash	4	5.6 (2.1 - 14.95)
	/	/	/	female genital tract fistula	4	4.55 (1.7 - 12.13)
	/	/	/			9.26 (2.98 - 28.81)
				genital ulceration	3	28.81)
	dyspnoea	957	2.05 (1.92 - 2.19)	interstitial lung disease	239	10.33 (9.09 - 11.74)
	pulmonary embolism	303	3.75 (3.35 - 4.2)	pulmonary embolism	141	2.91 (2.47 - 3.44)
	interstitial lung disease	220	5.65 (4.95 - 6.46)	pneumonitis	43	3.38 (2.51 - 4.56)
	respiratory failure	196	3.23 (2.81 - 3.72)	lung disorder	34	1.42 (1.01 - 1.98)
	pneumonitis	133	6.28 (5.29 - 7.45)	hypoxia	31	1.81 (1.27 - 2.57)
	pleural effusion	125	2.43 (2.04 - 2.9)	respiratory distress	27	1.97 (1.35 - 2.87)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	hypoxia	117	4.09 (3.41 - 4.91)	bronchospasm	20	2.77 (1.79 - 4.3)
	epistaxis	97	1.54 (1.26 - 1.87)	acute respiratory distress syndrome	17	1.94 (1.2 - 3.12)
	bronchospasm	96	8.01 (6.55 - 9.79)	pulmonary toxicity	16	4.92 (3.01 - 8.04)
	respiratory arrest	85	3.52 (2.84 - 4.35)	pulmonary artery thrombosis	12	31.47 (17.78 - 55.69)
	respiratory distress	82	3.58 (2.88 - 4.44)	hiccups	10	2.54 (1.37 - 4.73)
	pharyngeal inflammation	77	83.46 (66.18 - 105.27)	pneumomediastinum	9	11.08 (5.75 - 21.33)
	wheezing	73	1.55 (1.23 - 1.95)	laryngospasm	5	3.67 (1.52 - 8.81)
	acute respiratory distress syndrome	69	4.71 (3.72 - 5.97)	oropharyngeal blistering	5	5.87 (2.44 - 14.11)
	haemoptysis	60	2.54 (1.97 - 3.27)	pulmonary infarction	4	3.19 (1.2 - 8.52)
	pneumothorax	54	4.11 (3.15 - 5.37)	pulmonary pain	4	2.85 (1.07 - 7.59)
	aspiration	50	5.71 (4.32 - 7.54)	malignant pleural effusion	4	4.72 (1.77 - 12.59)
	tachypnoea	47	4.3 (3.23 - 5.72)	pulmonary granuloma	3	5.16 (1.66 - 16.03)
	throat tightness	45	2.01 (1.5 -	nasal inflammation	3	6.08 (1.96 -

		2.7)			18.89)
		7.22 (5.23 -			3.63 (1.17 -
laryngeal oedema	37	9.98)	nasal ulcer	3	11.27)
		4.43 (3.18 -			4.51 (1.45 -
lung infiltration	35	6.17)	pharyngeal ulceration	3	14.02)
		1.56 (1.04 -	/	/	/
pulmonary fibrosis	24	2.33)	/	/	/
		2.85 (1.91 -	/	/	/
atelectasis	24	4.26)	/	/	/
		1.62 (1.08 -	/	/	/
pharyngeal oedema	23	2.44)	/	/	/
obstructive airways		2.28 (1.5 -	/	/	/
disorder	22	3.47)	/	/	/
			/	/	/
asphyxia	21	3.07 (2 - 4.71)	/	/	/
		2.51 (1.56 -	/	/	/
pulmonary		4.05)	/	/	/
haemorrhage	17		/	/	/
		2.58 (1.6 -	/	/	/
hiccups	17	4.16)	/	/	/
		2.25 (1.35 -	/	/	/
apnoea	15	3.73)	/	/	/
		5.73 (3.39 -	/	/	/
stridor	14	9.7)	/	/	/
		8.83 (5 -	/	/	/
pneumomediastinum	12	15.59)	/	/	/
		14.96 (7.75 -	/	/	/
laryngeal disorder	9	28.89)	/	/	/
increased bronchial		3.84 (1.83 -	/	/	/
secretion	7	8.07)	/	/	/
pharyngeal		6.69 (3.18 -	/	/	/
haemorrhage	7	14.06)	/	/	/
		3.02 (1.44 -	/	/	/
lung consolidation	7	6.33)	/	/	/
bronchial		5.69 (2.71 -	/	/	/
obstruction	7	11.95)	/	/	/
		2.91 (1.39 -	/	/	/
pleuritic pain	7	6.12)	/	/	/
		15.32 (6.84 -	/	/	/
tracheal stenosis	6	34.3)	/	/	/
diffuse alveolar		6.07 (2.72 -	/	/	/
damage	6	13.54)	/	/	/
pulmonary artery		9.31 (4.17 -	/	/	/
thrombosis	6	20.79)	/	/	/

SKIN AND SUBCUTANEOUS TISSUE DISORDERS	nasal ulcer	5	3.62 (1.5 - 8.71)	/	/	/
	alveolitis	4	3.17 (1.19 - 8.45)	/	/	/
	malignant pleural effusion	4	2.82 (1.06 - 7.51)	/	/	/
	rhonchi	4	3.31 (1.24 - 8.83)	/	/	/
	pharyngeal paraesthesia	4	3.35 (1.25 - 8.94)	/	/	/
	pharyngeal ulceration	4	3.6 (1.35 - 9.6)	/	/	/
	laryngeal necrosis	3	84.25 (26.01 - 272.96)	/	/	/
	respiratory tract oedema	3	5.41 (1.74 - 16.82)	/	/	/
	laryngeal discomfort	3	5.96 (1.92 - 18.55)	/	/	/
	bronchostenosis	3	6.63 (2.13 - 20.63)	/	/	/
	pharyngeal stenosis	3	34.43 (10.9 - 108.7)	/	/	/
	sputum retention	3	4.05 (1.3 - 12.58)	/	/	/
	lung cyst	3	9.28 (2.98 - 28.92)	/	/	/
	pulmonary cavitation	3	4.37 (1.41 - 13.59)	/	/	/
	rash	1619	4.76 (4.53 - 5)	rash	1204	5.97 (5.63 - 6.32)
	dermatitis acneiform	574	132.56 (121.49 - 144.62)	dermatitis acneiform	651	258.74 (238.16 - 281.1)
	pruritus	509	1.76 (1.61 - 1.92)	skin toxicity	437	198.52 (179.73 - 219.27)
	erythema	389	2.28 (2.07 - 2.52)	dry skin	353	5.79 (5.21 - 6.43)
	dry skin	313	3.05 (2.73 - 3.41)	pruritus	249	1.44 (1.27 - 1.63)
	acne	251	3.84 (3.39 - 4.35)	skin disorder	230	14.16 (12.43 - 16.13)
	urticaria	241	1.81 (1.59 - 2.05)	erythema	215	2.11 (1.85 - 2.42)
	skin reaction	178	15.87 (13.69 - 18.41)	skin reaction	185	27.73 (23.97 - 32.07)

hyperhidrosis	163	1.49 (1.28 - 1.74)	acne	175	4.48 (3.86 - 5.2)
skin disorder	144	5.25 (4.46 - 6.19)	skin fissures	136	17.32 (14.63 - 20.52)
skin toxicity	139	34.66 (29.27 - 41.05)	dermatitis	95	10.17 (8.31 - 12.44)
skin fissures	136	10.32 (8.72 - 12.22)	palmar-plantar erythrodysaesthesia syndrome	93	7.97 (6.5 - 9.77)
dermatitis	121	7.74 (6.47 - 9.25)	skin exfoliation	92	2.34 (1.9 - 2.87)
skin exfoliation	119	1.8 (1.51 - 2.16)	skin lesion	66	4.86 (3.82 - 6.19)
rash pruritic	90	2.08 (1.69 - 2.55)	rash maculo-papular	58	5.45 (4.21 - 7.05)
nail disorder	89	13.42 (10.89 - 16.55)	rash pruritic	56	2.16 (1.66 - 2.81)
rash erythematous	72	2.03 (1.61 - 2.56)	skin ulcer	47	3.62 (2.72 - 4.82)
palmar-plantar erythrodysaesthesia syndrome	67	3.42 (2.69 - 4.34)	pain of skin	44	3.19 (2.38 - 4.29)
skin ulcer	49	2.25 (1.7 - 2.98)	rash erythematous	44	2.08 (1.55 - 2.79)
skin lesion	44	1.93 (1.44 - 2.59)	skin haemorrhage	33	5.15 (3.66 - 7.25)
skin haemorrhage	39	3.64 (2.65 - 4.98)	scab	32	5.79 (4.09 - 8.19)
rash maculo-papular	39	2.18 (1.59 - 2.99)	rash papular	31	2.7 (1.9 - 3.84)
rash papular	38	1.98 (1.44 - 2.72)	nail disorder	28	7.01 (4.83 - 10.16)
onychoclasia	33	5.8 (4.12 - 8.16)	photosensitivity	28	3.38 (2.33 - 4.89)
pain of skin	33	1.43 (1.02 - 2.01)	reaction	28	7.51 (4.98 - 11.31)
scab	33	3.56 (2.53 - 5.02)	pigmentation	23	1.96 (1.29 - 2.98)
hair growth	30	5.17 (3.61 - 7.4)	disorder	22	4.71 (3.07 - 7.23)
abnormal	30	1.9 (1.31 - 2.76)	stevens-johnson syndrome	21	2.37 (1.53 - 3.67)
cold sweat	28	2.16 (1.41 - 3.31)	hypertrichosis	18	18.47 (11.61 - 29.39)
dermatitis allergic	21				

		2.68 (1.72 -			4.86 (2.97 -
purpura	20	4.15)	papule	16	7.94)
nail bed		65.95 (39.8 -			3.02 (1.82 -
inflammation	16	109.27)	toxic skin eruption	15	5.01)
		3.61 (2.21 -			121.55 (70.73 -
skin necrosis	16	5.9)	xeroderma	14	208.88)
		29.38 (17.59 -			3.81 (2.21 -
cutaneous symptom	15	49.08)	onychoclasia	13	6.57)
		6.52 (3.86 -			2.8 (1.62 -
exfoliative rash	14	11.03)	erythema multiforme	13	4.82)
dermatitis		3.13 (1.85 -	nail bed		88.74 (50.84 -
exfoliative	14	5.29)	inflammation	13	154.9)
		2.54 (1.5 -	skin		2.8 (1.59 -
papule	14	4.29)	hyperpigmentation	12	4.94)
		7.94 (4.6 -			3.81 (2.16 -
hypertrichosis	13	13.7)	sensitive skin	12	6.72)
		4.49 (2.61 -			3.16 (1.75 -
onychomadesis	13	7.75)	hair growth abnormal	11	5.72)
		3.63 (2.06 -			3.77 (2.03 -
nail discolouration	12	6.39)	skin necrosis	10	7.02)
		12.25 (6.57 -			7.79 (4.18 -
onychalgia	10	22.86)	exfoliative rash	10	14.5)
		6.35 (3.17 -			11.98 (6.22 -
onycholysis	8	12.73)	onycholysis	9	23.08)
		2.14 (1.07 -			3.24 (1.68 -
rash vesicular	8	4.29)	hyperkeratosis	9	6.22)
		3.42 (1.63 -			4.62 (2.31 -
ingrowing nail	7	7.18)	onychomadesis	8	9.26)
		56.6 (26.46 -			3.14 (1.5 -
rash follicular	7	121.06)	rash vesicular	7	6.59)
		15.66 (7.43 -			3.54 (1.69 -
nail bed bleeding	7	33.03)	nail discolouration	7	7.43)
		3.5 (1.57 -			4.69 (2.23 -
livedo reticularis	6	7.8)	skin erosion	7	9.84)
seborrhoeic		4.62 (2.07 -	seborrhoeic		7.73 (3.47 -
dermatitis	6	10.3)	dermatitis	6	17.25)
		5.22 (2.17 -			4.09 (1.7 -
palmar erythema	5	12.57)	ingrowing nail	5	9.83)
		11.57 (4.32 -			7.31 (3.04 -
nail bed disorder	4	30.99)	hirsutism	5	17.59)
		4.7 (1.76 -			77.07 (31.48 -
skin oedema	4	12.54)	mucocutaneous rash	5	188.67)
subcutaneous		5.13 (1.92 -			16.11 (6.68 -
emphysema	4	13.7)	cutaneous symptom	5	38.86)

SOCIAL CIRCUMSTANCES	hirsutism	4	3.49 (1.31 - 9.31)	livedo reticularis	5	4.89 (2.03 - 11.75)
	nail toxicity	4	18.64 (6.94 - 50.1)	onychalgalia	5	10.21 (4.24 - 24.58)
	hypotrichosis	3	5.1 (1.64 - 15.85)	henoch-schonlein purpura	4	3.96 (1.49 - 10.57)
	nail bed tenderness	3	31.08 (9.86 - 97.97)	panniculitis	4	3.3 (1.24 - 8.79)
	/	/	/	hypersensitivity	4	2.8 (1.05 - 7.46)
	/	/	/	vasculitis	4	38.04 (12.12 - 119.37)
	/	/	/	rash papulosquamous	3	9.91 (3.19 - 30.84)
	/	/	/	dermatosis	3	12.71 (4.08 - 39.57)
	/	/	/	perioral dermatitis	3	5.89 (1.9 - 18.31)
	/	/	/	skin oedema	3	39.44 (12.56 - 123.82)
	/	/	/	rash follicular	3	11.79 (3.79 - 36.69)
	refusal of treatment by patient	11	1.93 (1.07 - 3.48)	intertrigo	3	4.11 (2.43 - 6.95)
	social problem	7	2.14 (1.02 - 4.5)	refusal of treatment by patient	14	/
	tracheostomy	13	11.27 (6.53 - 19.47)	/	/	/
	hepatectomy	11	50.83 (27.76 - 93.07)	surgery	52	1.99 (1.51 - 2.61)
SURGICAL AND MEDICAL PROCEDURES	cancer surgery	9	11.71 (6.07 - 22.6)	hepatectomy	16	126.63 (76.25 - 210.28)
	lymphadenectomy	8	9.87 (4.92 - 19.8)	hospice care	10	2.19 (1.18 - 4.07)
	leg amputation	8	2.25 (1.12 - 4.5)	cancer surgery	7	15.23 (7.24 - 32.04)
	gastrostomy	7	5.89 (2.8 - 12.38)	colostomy	6	6.34 (2.84 - 14.13)
	ileostomy	6	3.12 (1.4 - 6.94)	radiotherapy	5	5.93 (2.47 - 14.27)
	gastrointestinal tube insertion	6	3.02 (1.36 - 6.74)	liver operation	5	38.53 (15.89 - 93.46)
	resuscitation	6	4.19 (1.88 - 9.33)	depilation	5	372.49 (142.11 - 976.35)
				nephrostomy	3	20.16 (6.46 - 62.92)

VASCULAR DISORDERS	colostomy	5	3.15 (1.31 - 7.58)	palliative care	3	4.5 (1.45 - 13.98)
	tumour excision	4	6.1 (2.28 - 16.3)	/	/	/
	gastrointestinal surgery	4	6.56 (2.45 - 17.53)	/	/	/
	proctectomy	4	20.23 (7.52 - 54.41)	/	/	/
	liver operation	3	13.68 (4.38 - 42.73)	/	/	/
	laryngectomy	3	55.2 (17.3 - 176.18)	/	/	/
	colon operation	3	3.26 (1.05 - 10.14)	/	/	/
	colostomy closure	3	11.81 (3.79 - 36.86)	/	/	/
	hypotension	660	4 (3.71 - 4.32)	deep vein thrombosis	71	2.11 (1.67 - 2.67)
	flushing	235	2.71 (2.39 - 3.08)	embolism	21	4.93 (3.21 - 7.57)
	deep vein thrombosis	198	3.53 (3.07 - 4.06)	venous thrombosis	16	8.16 (4.99 - 13.33)
	thrombosis	95	1.39 (1.14 - 1.71)	infarction	9	2.47 (1.29 - 4.75)
	cyanosis	68	5.14 (4.05 - 6.52)	vena cava thrombosis	8	9.45 (4.72 - 18.93)
	pallor	52	2.24 (1.71 - 2.94)	hypovolaemic shock	7	3.02 (1.44 - 6.35)
	shock	43	2.34 (1.74 - 3.16)	venous thrombosis	7	6.15 (2.93 - 12.91)
	circulatory collapse	43	2.93 (2.17 - 3.96)	limb	7	9.97 (4.47 - 22.24)
	embolism	31	4.35 (3.06 - 6.2)	embolism arterial	6	6.81 (3.05 - 15.18)
	venous thrombosis	20	6.09 (3.93 - 9.46)	jugular vein thrombosis	6	4.11 (1.85 - 9.17)
	peripheral ischaemia	19	5.54 (3.53 - 8.69)	embolism venous	6	3.28 (1.47 - 7.3)
	hypovolaemic shock	18	4.65 (2.93 - 7.39)	thrombophlebitis	6	4.07 (1.53 - 10.87)
	vena cava thrombosis	16	11.34 (6.93 - 18.56)	hyperaemia	4	9.75 (3.14 - 30.33)
	venous thrombosis	13	6.84 (3.96 - 11.79)	superior vena cava syndrome	3	/
	limb			/	/	/

jugular vein thrombosis	13	8.84 (5.12 - 15.27)	/	/	/
subclavian vein thrombosis	12	12.16 (6.89 - 21.49)	/	/	/
hyperaemia	12	7.33 (4.16 - 12.94)	/	/	/
arterial haemorrhage	9	9.77 (5.07 - 18.84)	/	/	/
phlebitis	9	2.02 (1.05 - 3.89)	/	/	/
peripheral arterial occlusive disease	8	2.32 (1.16 - 4.65)	/	/	/
axillary vein thrombosis	7	23.35 (11.04 - 49.37)	/	/	/
aortic thrombosis	6	6.64 (2.97 - 14.81)	/	/	/
pelvic venous thrombosis	6	4.86 (2.18 - 10.83)	/	/	/
thrombophlebitis migrans	6	26.91 (11.97 - 60.5)	/	/	/
peripheral artery thrombosis	5	4.29 (1.78 - 10.32)	/	/	/
arterial thrombosis	5	3.04 (1.26 - 7.31)	/	/	/
extremity necrosis	5	3.43 (1.43 - 8.26)	/	/	/
embolism arterial	4	3.96 (1.48 - 10.57)	/	/	/
hypoperfusion	3	3.55 (1.14 - 11.04)	/	/	/
superficial vein thrombosis	3	6.39 (2.05 - 19.88)	/	/	/
femoral artery embolism	3	57.17 (17.9 - 182.66)	/	/	/

Abbreviations: FAERS, FDA Adverse Event Reporting System; PTs, preferred terms; ROR, reported odds ratio; SOC, systemic organ classes.

Supplementary Table 6. The top 20 concomitant drugs with cetuximab and panitumumab (N=102,125).

Concomitant drugs	Number	Ratio (%)
Fluorouracil	10288	10.07%
Calcium folinate	5837	5.72%
Irinotecan	5081	4.98%
Oxaliplatin	4675	4.58%
Cisplatin	2329	2.28%
Carboplatin	1529	1.50%
Dexamethasone	1411	1.38%
Benadryl	1406	1.38%
Paclitaxel	1237	1.21%
Ondansetron	820	0.80%
Capecitabine	714	0.70%
Bevacizumab	571	0.56%
Docetaxel	448	0.44%
Aspirin	415	0.41%
Polaramine	394	0.39%
Gemcitabine	376	0.37%
Palonosetron	355	0.35%
Prochlorperazine	302	0.30%
Granisetron	299	0.29%
Oxycontin	267	0.26%